Market Insider

In this article

A shopper loads a car with bottled water at a Costco Wholesalers in Chingford, Britain March 15, 2020.
John Sibley | Reuters

Check out the companies making headlines in midday trading.

Salesforce — Shares of the cloud-based software company slid more than 9% after the firm announced the sudden departure of co-CEO Bret Taylor. The Dow component dragged down the 30-stock average during Thursday’s sell-off. Salesforce did report earnings and revenue that beat analyst expectations for the most recent quarter, however.

Costco – Shares of retailer Costco shed nearly 6% after the company reported softer-than-expected sales figures for November that could signal a weak consumer heading into the holiday shopping season. The company announced that sales in November rose 5.7% to $19.17 billion on the year, less than the growth seen in October and September.

Snowflake — Shares of Snowflake gained more than 4% after analysts from Morgan Stanley and MoffettNathanson reiterated their bullish stance on the stock’s long-term prospects. The cloud data platform provider reported earnings that beat expectations but provided light revenue guidance, which sent the stock lower after-hours Wednesday.

Okta — The identity management software provider’s stock surged more than 23% after the company shared a better-than-expected outlook and topped Wall Street’s estimates for the recent period. Analysts had anticipated a loss of 24 cents for the quarter.

Five Below – Shares of the discount retailer jumped more than 13% after Five Below beat estimates on the top and bottom lines for the latest quarter. The company reported 29 cents of earnings per share on $645 million of revenue. Analysts surveyed by Refinitiv were expecting 14 cents of earnings per share and $613 million of revenue. Fourth-quarter guidance also topped expectations. CEO Joel Anderson said in a statement that ticket and transaction metrics improved during the third quarter.

Victoria’s Secret — Shares fell 4% after Victoria’s Secret reported mixed results from its most recent quarter. The lingerie company reported earnings of 29 cents per share on revenue of $1.32 billion. Analysts polled by Refinitiv were expecting earnings of 23 cents per share on revenue of $1.33 billion. JPMorgan downgraded the stock to neutral from overweight after the results, citing trouble in the company’s core business.

PVH — Shares surged 10% after PVH surpassed Wall Street’s expectations and posted strong quarterly guidance, saying it expects full-year revenues to finish within the higher end of its expected range.

Splunk — Splunk’s stock added 13% on solid quarterly results and an upbeat full-year forecast. The company also noted benefits from cost-cutting.

Designer Brands – Shares of the footwear retailer tumbled 22% after the company reported quarterly earnings and revenue that missed Wall Street estimates. It also cut its profit outlook, citing the volatile economic environment.

Dollar General – The discount retailer saw its shares drop more than 8% after posting earnings for the latest quarter than fell short of analysts’ expectations by 21 cents per share and lowered its annual forecast due to higher costs.

Aclaris Therapeutics — Shares jumped 3.5% after Goldman Sachs initiated coverage on Aclaris Therapeutics with a buy rating. The firm said the biopharma stock could jump more than 60% on a possible new treatment for immuno-inflammatory diseases.

Nutanix — Nutanix’s stock gained 5.8% amid a Bloomberg report that Hewlett Packard Enterprise has recently held potential takeover talks with the cloud computing company, citing sources familiar with the situation.

Lands’ End — Shares toppled 30% after the apparel retailer posted an unexpected loss for the recent quarter and revenue fell short of analysts’ expectations.

Ally Financial — Ally Financial’s stock slipped 3.8% following a downgrade to underweight by Morgan Stanley, citing a cautious consumer credit outlook ahead.

GoodRx — The stock jumped 13% after Citi initiated coverage of the discount drugs app with a buy rating and said the selloff in shares of GoodRx is overdone. The firm’s target suggests potential upside of more than 60%.

— CNBC’s Sarah Min, Tanaya Macheel, Michelle Fox, Jesse Pound, Carmen Reinicke and Yun Li contributed reporting

Articles You May Like

Data centers powering artificial intelligence could use more electricity than entire cities
Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy’s playbook
5 Moonshot Stocks to Buy for 2025 
Activist Ananym has a list of suggestions for Henry Schein. How the firm can help improve profits
Quantum Computing: The Key to Unlocking AI’s Full Potential?